Important Identity Correction

What Is Thymalfasin?

First, Thymalfasin is the chemically synthesized form of thymosin alpha-1, a naturally occurring 28-amino-acid peptide derived from the N-terminal region of prothymosin alpha.

Next, thymosin alpha-1 was first isolated from thymosin fraction 5, a thymus-derived peptide preparation. The synthetic drug form is marketed internationally under names including Zadaxin.

However, unlike short organ-specific peptide bioregulators such as Vilon or Thymogen, thymalfasin is a comparatively large, completely characterized immunoregulatory peptide with decades of experimental and clinical research.

🧬 Molecular Structure

First, thymalfasin is an acidic, N-terminally acetylated linear peptide containing 28 amino-acid residues. It is chemically identical in sequence to human thymosin alpha-1.

🧪 Complete Amino-Acid Sequence

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH

One-letter notation:

Ac-SDAAVDTSSEITTKDLKEKKEVEEEAEN-OH

⚛️ Molecular Weight and 🧫 Formula

📅 Discovery Timeline and Research History

1960s–1970s: Thymosin fraction 5 developed

First, researchers extracted and fractionated peptides from calf thymus to identify factors involved in immune development.

1977: Thymosin alpha-1 isolated and sequenced

Next, researchers determined the complete 28-amino-acid sequence and established thymosin alpha-1 as one of the first fully characterized thymic peptides.

1980s–1990s: Synthetic thymalfasin developed

Moreover, researchers produced chemically synthesized thymosin alpha-1 for standardized experimental and pharmaceutical use.

1990s–2000s: International clinical development

In addition, researchers evaluated thymalfasin in chronic hepatitis B and C, immunodeficiency, cancer, vaccine-response studies, and infection-related immune dysfunction.

2000: FDA orphan designation

However, the FDA granted orphan-drug designation for thymalfasin in hepatocellular carcinoma, but this did not constitute FDA approval.

2010s: Sepsis, oncology, and vaccine-response research expands

Meanwhile, investigators studied thymalfasin as an immune adjunct in critical illness, malignancy, and immunocompromised populations.

2020–2025: COVID-19 and immune-reconstitution research

Moreover, clinical trials and reviews explored thymalfasin in severe viral illness, lymphocyte recovery, immune homeostasis, and vaccine response.

Current status

Finally, multiple countries use or approve thymalfasin, but the FDA has not approved it in the United States.

Thymus and Immune-System Biology

Thymic T-cell development

First, the thymus supports T-cell lineage commitment, positive selection, negative selection, and development of immune tolerance.

CD4 and CD8 cells

Next, CD4 T cells coordinate immune responses, while CD8 T cells kill infected or malignant cells. Their function depends on antigen presentation, cytokines, costimulation, and tissue context.

Dendritic cells

Moreover, dendritic cells detect pathogens, process antigens, and activate naïve T cells. They bridge innate and adaptive immunity.

Innate immunity

In addition, macrophages, natural killer cells, neutrophils, and pattern-recognition receptors provide early defense and shape later adaptive responses.

Immune homeostasis

Finally, effective immunity requires balance. Excessive activation can cause tissue injury, while insufficient activation can permit infection or malignancy.

🧠 Mechanism of Action

Importantly, thymalfasin appears to modulate both innate and adaptive immunity. Its action is pleiotropic rather than limited to one receptor.

1. Toll-like receptor signaling

First, research has linked thymosin alpha-1 with Toll-like receptor pathways, particularly Next, TLR2 and TLR9 in dendritic and myeloid cells.

2. Dendritic-cell maturation

Next, thymalfasin can enhance antigen presentation, expression of costimulatory molecules, and dendritic-cell functional maturation.

3. T-cell differentiation and survival

Moreover, studies report effects on T-cell maturation, CD4 and CD8 responses, cytokine production, and protection of thymocytes from steroid-induced apoptosis.

4. Natural killer-cell activity

In addition, researchers have associated thymosin alpha-1 with enhanced NK-cell cytotoxicity in selected models.

5. Cytokine modulation

However, reported effects include changes in interferons, interleukins, chemokines, and Th1-associated signaling. However, responses depend on disease state and immune context.

🎯 Receptor and Pathway Profile

T-Cell and Adaptive Immune Research

T-cell maturation

First, thymosin alpha-1 was initially identified because of its ability to support thymus-dependent lymphocyte differentiation and function.

CD4 and CD8 populations

Next, clinical and preclinical studies report changes in CD4 counts, CD8 activity, CD4:CD8 ratios, or functional T-cell responses in selected immunocompromised populations.

Vaccine responses

Moreover, researchers have investigated thymalfasin as an adjunct to improve vaccine immunogenicity in older adults or immunocompromised individuals.

Antiviral immunity

In addition, research has evaluated thymalfasin in chronic hepatitis, severe viral infection, and other conditions where T-cell dysfunction may impair viral clearance.

Not a universal immune stimulant

However, responses depend on baseline immune status, pathogen, timing, concurrent therapy, age, and disease severity.

Dendritic-Cell and Innate Immune Research

Dendritic cells

First, thymalfasin may increase dendritic-cell maturation, antigen presentation, and cytokine production.

Pattern-recognition receptors

Next, TLR2 and TLR9 signaling may help explain effects on pathogen recognition and adaptive immune activation.

Natural killer cells

Moreover, researchers have reported increased NK-cell activity in infection and cancer-related studies.

Macrophage signaling

In addition, thymalfasin can alter inflammatory cytokine responses, but whether this is stimulatory or regulatory depends on the immune environment.

Immune homeostasis

However, researchers often describe the peptide as an immune modulator rather than a simple stimulant because it may restore weak responses while limiting dysregulated inflammation in some models.

Clinical Research and International Use

Chronic hepatitis B and C

First, thymalfasin has been approved or used in some countries as an adjunct in chronic viral hepatitis. Results vary by antiviral regimen and study era.

Cancer adjunct research

Next, studies have evaluated thymalfasin with chemotherapy, immunotherapy, or other cancer treatments. It is not an established standalone anticancer drug.

Sepsis and critical illness

Moreover, trials and meta-analyses have examined mortality, infection, lymphocyte recovery, and ICU outcomes. Findings are mixed and study quality varies.

Vaccine response

In addition, research has explored improved influenza, hepatitis, and other vaccine responses in populations with reduced immune responsiveness.

COVID-19

However, trials investigated immune recovery, lymphocyte counts, severity, and mortality. Evidence remains insufficient for routine universal use.

Regulatory distinction

Finally, approval in another country does not mean FDA approval in the United States. FDA orphan designation also does not equal marketing approval.

Immunosenescence and Healthy-Aging Research

Age-related thymic involution

First, the thymus shrinks with age, reducing naïve T-cell output and narrowing immune repertoire diversity.

Older-adult immune responses

Next, researchers have studied thymalfasin for vaccine-response enhancement and immune restoration in older or immunocompromised adults.

No proven thymic regrowth

However, no robust evidence shows that thymalfasin physically regrows the aged human thymus or restores it to a youthful state.

No established longevity effect

Moreover, researchers have not proven that thymalfasin extends human lifespan or broadly reverses biological aging.

Immune aging is multifactorial

Finally, nutrition, chronic infection, inflammation, frailty, medications, cancer, metabolic disease, and bone-marrow function all contribute to immune decline.

Evidence Limitations and Clinical Interpretation

Heterogeneous trials

First, studies vary in population, dose, duration, disease severity, concurrent therapy, and endpoints.

Regional availability

Next, some clinical experience comes from countries with regulatory systems and treatment practices different from those in the United States.

Adjunctive use complicates interpretation

Moreover, many studies combine thymalfasin with antiviral drugs, chemotherapy, vaccines, antibiotics, or supportive care.

Biomarkers are not always clinical outcomes

However, higher lymphocyte counts or cytokine changes do not automatically translate into fewer infections, longer survival, or better quality of life.

No universal immune indication

Finally, marketers should not present thymalfasin as appropriate for every infection, cancer, or low-immunity state.

Safety and Regulatory Considerations

General tolerability

First, international studies generally describe thymalfasin as well tolerated, with injection-site reactions and mild systemic symptoms among the more commonly reported adverse effects.

Potential adverse effects

• First, Injection-site pain, redness, or swelling
• Next, Fatigue or transient flu-like symptoms
• Also, Headache
• Moreover, Nausea
• In addition, Possible changes in inflammatory or autoimmune activity

Autoimmune disease

Moreover, immune modulation could theoretically worsen some autoimmune conditions or interact with immunosuppressive therapy.

Transplantation

In addition, immune-enhancing effects may be inappropriate in transplant recipients without specialist oversight.

Cancer treatment

However, use alongside chemotherapy, checkpoint inhibitors, cellular therapy, or immunosuppressive regimens requires oncology supervision.

United States regulatory status

Finally, thymalfasin is not FDA approved. It received orphan designation for selected indications, but orphan designation is not approval.

🧪 Laboratory Testing Methods

Identity, Sequence, Acetylation, and Potency Testing

📄 How to Interpret a Thymalfasin COA

COA Review and Route-Specific Quality

1. By contrast, Verify the exact identity: The COA should state thymalfasin or thymosin alpha-1.
2. Also, Confirm the full 28-amino-acid sequence: A generic “thymic peptide” label is inadequate.
3. Consequently, Verify N-terminal acetylation: The sequence must begin with acetylated serine.
4. However, Confirm molecular mass: Approximately 3108.3 g/mol.
5. Therefore, Separate purity from net content: A 99% HPLC area result does not prove the labeled peptide amount.
6. For example, Review truncations, deletion peptides, oxidation, deamidation, and aggregation.
7. Meanwhile, Check water, counterions, residual solvents, and elemental impurities.
8. Likewise, Match microbiological testing to the route: Injectable material requires validated sterility and endotoxin testing.
9. In addition, Do not infer clinical efficacy: A COA cannot prove improved immunity, infection prevention, vaccine response, cancer benefit, or thymic rejuvenation.

📊 Thymalfasin vs Thymogen vs Vilon vs Thymalin

Large Defined Peptide Versus Ultrashort Thymic Peptides

Thymalfasin vs Thymosin Beta-4

Thymalfasin vs Approved Immune Therapies

International Immune Modulator Versus Approved U.S. Therapies

🔗 Related Peptides and Immune Pathways

• Prothymosin alpha: First, the precursor protein from which thymosin alpha-1 derives.
• Next, TLR2 and TLR9: Pattern-recognition pathways associated with thymosin alpha-1 activity.
• Dendritic cells: Also, Antigen-presenting cells central to thymalfasin research.
• CD4 and CD8 T cells: Moreover, Adaptive immune populations influenced in selected studies.
• Natural killer cells: In addition, Innate lymphocytes reported to respond to thymosin alpha-1.
• Thymogen and Vilon: Likewise, Distinct ultrashort thymic peptides.
• Thymalin: Finally, Complex thymus-derived peptide mixture.

🖼️ Original Diagram Specifications

Diagram 1: Thymalfasin primary structure

Also, Show the full 28-amino-acid chain with the N-terminal acetyl group, acidic residues, lysine clusters, and free C-terminal carboxyl group.

Diagram 2: Identity correction

Consequently, Contrast the unrecognized term “Thymaifasin” with thymalfasin, thymosin alpha-1, and the Zadaxin trade name.

Diagram 3: Innate-to-adaptive immune bridge

However, Show TLR2/TLR9 signaling in dendritic cells, antigen presentation, T-cell activation, NK-cell support, and antibody responses.

Diagram 4: Thymic T-cell development

Therefore, Show bone-marrow progenitors entering the thymus, positive and negative selection, and mature CD4/CD8 T-cell release.

Diagram 5: Clinical evidence map

For example, Show chronic viral hepatitis, cancer adjunct research, sepsis, vaccine response, COVID-19, and immunocompromised states, with evidence strength graded separately.

Diagram 6: Regulatory-status map

Meanwhile, Show international approvals or marketing versus lack of FDA approval and the distinction between orphan designation and approval.

Diagram 7: COA workflow

Likewise, Show intact mass, full MS/MS sequence, N-terminal acetylation, peptide mapping, amino-acid analysis, net content, impurities, sterility, endotoxin, and stability.

❓ Frequently Asked Questions

Is “Thymaifasin” a recognized peptide?

In addition, No reliable primary source was found for that spelling. The intended compound is almost certainly thymalfasin.

Is thymalfasin a peptide?

Moreover, Yes. It is a synthetic, N-terminally acetylated 28-amino-acid peptide.

Is thymalfasin the same as thymosin alpha-1?

By contrast, Yes. Thymalfasin is the chemically synthesized drug form of thymosin alpha-1.

What is its sequence?

Ac-SDAAVDTSSEITTKDLKEKKEVEEEAEN-OH.

What is its molecular weight?

Approximately 3108.3 g/mol.

Is thymalfasin FDA approved?

Also, No. It has FDA orphan designations but no FDA marketing approval.

Is it approved elsewhere?

Consequently, multiple countries have approved or marketed it for selected indications.

Does thymalfasin increase T cells?

Moreover, studies report effects on T-cell maturation, function, and counts in selected populations, but results vary.

Does it improve immunity?

However, It may improve selected immune responses in some immunocompromised or infected populations, but it is not a universal immune booster.

Does thymalfasin regrow the thymus?

However, no robust evidence shows physical regrowth of an aged human thymus.

Is it used for cancer?

Therefore, researchers have studied it as an adjunct rather than as a proven standalone cancer treatment.

Is thymalfasin the same as TB-500?

For example, No. TB-500 is associated with thymosin beta-4 and is chemically unrelated.

Does 99% HPLC purity prove immune activity?

Meanwhile, No. Full sequence, acetylation, net content, potency, safety, pharmacokinetics, and clinical outcomes must be established separately.

Thymalfasin Scientific Overview: Final Thoughts

In conclusion, the original article appears to be based on a misspelling. The recognized compound is thymalfasin, the synthetic form of thymosin alpha-1—not a proprietary ultrashort Khavinson peptide.

However, thymalfasin is a fully characterized, N-terminally acetylated 28-amino-acid peptide with decades of research involving dendritic cells, Next, TLR2 and TLR9 pathways, T-cell responses, natural killer cells, chronic viral hepatitis, cancer adjunct therapy, sepsis, vaccine responses, and immune reconstitution.

Therefore, its international use and clinical literature make it more established than most research peptides, but the FDA has not approved it, and marketers should not present it as a universal immune enhancer, anti-aging treatment, or substitute for standard care.

📚 References

Thymalfasin Identity, Mechanism, and Clinical Sources

1. Likewise, Goldstein AL, et al. Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide. 1977.
2. In addition, PubChem. Thymalfasin compound record.
3. Moreover, Dominari A, et al. Thymosin alpha-1: A comprehensive review of the literature. 2020.
4. By contrast, Li J, et al. Thymosin alpha 1: biological activities, applications and genetic engineering production. 2010.
5. Also, Sjögren MH. Thymalfasin: an immune system enhancer for chronic hepatitis and related diseases. 2004.
6. Consequently, FDA. Orphan-drug designation record for thymalfasin.
7. However, FDA. Thymosin Alpha-1 related bulk drug substances review. 2024.
8. Therefore, ClinicalTrials.gov. Thymalfasin for COVID-19 infection.
9. For example, ClinicalTrials.gov. Thymalfasin vaccine-response and immune-reconstitution studies.
10. Meanwhile, Garaci E. Thymosin alpha1: a historical overview. Annals of the New York Academy of Sciences.
11. Likewise, Romani L, et al. Thymosin alpha1 activates dendritic cells through Toll-like receptor signaling. Blood and related immunology literature.
12. In addition, Romani L, et al. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nature Medicine.
13. Moreover, Serafino A, et al. Thymosin alpha1 activates dendritic cells and protects against fungal infection. Immunology literature.
14. By contrast, Naylor PH, et al. Thymosin alpha1 and T-cell differentiation. International Journal of Immunopharmacology.
15. Also, Low TLK, et al. Thymosin alpha1 effects on lymphocyte maturation and function. Journal of Biological Response Modifiers.
16. Consequently, Schulof RS. Thymic hormones and immune restoration. Cancer Treatment Reports.
17. However, Goldstein AL, et al. Thymosins and immune regulation. Annals of the New York Academy of Sciences.
18. Therefore, Tuthill C, et al. Thymalfasin and chronic hepatitis B. Journal of Viral Hepatitis.
19. For example, Sherman KE, et al. Thymosin alpha1 and chronic hepatitis C combination therapy.
20. Meanwhile, Andreone P, et al. Thymosin alpha1 plus interferon in chronic hepatitis C.
21. Likewise, Rasi G, et al. Thymosin alpha1 in hepatocellular carcinoma and cancer immunotherapy.
22. In addition, Maio M, et al. Thymosin alpha1 in melanoma and oncology adjunct research.
23. Moreover, Schulof RS, et al. Thymosin alpha1 in lung cancer immunotherapy. Journal of Biological Response Modifiers.
24. By contrast, King R, Tuthill C. Immune-modulating properties of thymosin alpha1. Expert Opinion on Biological Therapy.

Immune, Regulatory, and Analytical Sources

25. Also, Matteucci C, et al. Thymosin alpha1 and immune homeostasis. Annals of the New York Academy of Sciences.
26. Consequently, Garaci E, et al. Thymosin alpha1 in sepsis and severe infection. Expert Opinion on Biological Therapy.
27. However, Liu F, et al. Thymosin alpha1 for sepsis: systematic review and meta-analysis.
28. Therefore, Wu J, et al. Thymosin alpha1 in severe sepsis and lymphocyte recovery.
29. For example, Pei F, et al. Thymosin alpha1 treatment in critical illness and infection.
30. Meanwhile, Matteucci C, et al. Thymosin alpha1 and dendritic-cell function.
31. Likewise, Bistoni F, et al. Thymosin alpha1 and antifungal immunity.
32. In addition, Wolf E, et al. Thymosin alpha1 as an adjuvant to vaccination in immunocompromised hosts.
33. Moreover, Ershler WB, et al. Thymosin alpha1 and influenza vaccine response in older adults.
34. However, Rinaldi M, et al. Thymosin alpha1 and vaccine immunogenicity.
35. Therefore, Peppas S, et al. Thymosin alpha1 in chronic viral infection.
36. Likewise, Matteucci C, et al. Thymosin alpha1 and innate immunity.
37. For example, Pica F, et al. Thymosin alpha1 in infectious diseases. Expert Opinion on Biological Therapy.
38. Moreover, Riva A, et al. Thymosin alpha1 in COVID-19: mechanistic and clinical review.
39. In addition, Yu K, et al. Thymosin alpha1 in COVID-19 patients with severe lymphocytopenia.
40. However, Liu Y, et al. Thymosin alpha1 and outcomes in severe COVID-19.
41. Therefore, Blood Neoplasia. Thymic peptides in immune reconstitution and clinical practice. 2025.
42. Likewise, Besman M, et al. Review of thymic peptides and hormones. 2024.
43. For example, ICH Q2(R2). Validation of Analytical Procedures.
44. Moreover, USP General Chapter <621>. Chromatography.
45. In addition, USP General Chapter <71>. Sterility Tests.
46. USP General Chapter <85>. Bacterial Endotoxins Test.
47. USP General Chapters <232> and <233>. Elemental Impurities.
48. ICH Q3C. Residual Solvents.
49. ICH Q1A(R2). Stability Testing of New Drug Substances and Products.

Identity, molecular properties, immune mechanisms, international clinical research, regulatory status, safety, and analytical requirements were reviewed in July 2026. Thymalfasin remains unapproved by the FDA in the United States.